Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -39K | -9K | 0 | -36K |
| Operating Income | -71M | -37M | -32M | -14M | -21M |
| EBITDA | -71M | -35M | -32M | -14M | -21M |
| Net Income | -69M | -35M | -31M | -14M | -22M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$18.79
+1.35% today
1Y Change
+75.07%
Window
Jun 25, 2025 → Jun 24, 2026
Coverage: 250 bars · Jun 25, 2025 → Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Forte Biosciences, Inc. (FBRX) is a Healthcare stock with a market cap of $370.00M and listed on NASDAQ. The stock last traded around $18.79 and up 75.1% across the available one-year price window (Jun 25, 2025 → Jun 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +61.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +61.3%, free cash flow -65.7% with operating margin 0.0% and ROIC -113.9%. Stock Foundry combines FBRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
FBRX
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
FBRX Max Drawdown
-55.90%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for FBRX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$21.7M
-56.6% YoY
Free Cash Flow
-$16.7M
-103.8% YoY
Revenue Growth
+0.0%
EPS Growth
+61.3%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -39K | -9K | 0 | -36K |
| Operating Income | -71M | -37M | -32M | -14M | -21M |
| EBITDA | -71M | -35M | -32M | -14M | -21M |
| Net Income | -69M | -35M | -31M | -14M | -22M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 77M | 22M | 12M | 41M | 42M |
| Total Assets | 83M | 62M | 39M | 42M | 43M |
| Total Liabilities | 22M | 9M | 4M | 3M | 2M |
| Shareholder Equity | 61M | 52M | 35M | 39M | 42M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -77M | -22M | -12M | -41M | -42M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
17M
-103.8% YoY
Capital Expenditures
0
Free Cash Flow
17M
-103.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-98.4%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.